Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
IPO Year: 2020
Exchange: NASDAQ
Website: zentalis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/12/2024 | $4.00 | Underperform → Neutral | Wedbush |
| 6/20/2024 | $28.00 → $5.00 | Buy → Neutral | UBS |
| 6/18/2024 | $42.00 → $6.00 | Buy → Hold | Jefferies |
| 6/18/2024 | $38.00 → $8.00 | Overweight → Equal-Weight | Morgan Stanley |
| 6/18/2024 | $15.00 → $4.00 | Neutral → Underperform | Wedbush |
| 6/18/2024 | Overweight → Equal Weight | Wells Fargo | |
| 11/8/2023 | $38.00 → $12.00 | Outperform → Neutral | Wedbush |
| 11/7/2023 | $15.00 | Outperform → Market Perform | Leerink Partners |
| 7/12/2022 | Outperform | Cowen | |
| 4/6/2022 | $67.00 | Overweight | Wells Fargo |
FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the
ORR of 36.8% in heavily pretreated platinum-resistant ovarian cancer and USC patients treated with intermittent dosing Establishes monotherapy RP2D of 400 mg QD with 5:2 dosing schedule; New RP2D more than doubles exposure levels, maintains safety and improves tolerability with no treatment-related discontinuations Company plans to update efficacy data from Phase 1 monotherapy dose optimization study and provide program timeline updates for three azenosertib Phase 2 monotherapy trials currently enrolling patients at the RP2D in the second half of 2023 Investor call at 8:00 a.m. ET today to review azenosertib monotherapy data supporting dose selection and chemotherapy combination da
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
SC 13G/A - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
Wedbush upgraded Zentalis Pharma from Underperform to Neutral and set a new price target of $4.00
UBS downgraded Zentalis Pharma from Buy to Neutral and set a new price target of $5.00 from $28.00 previously
Jefferies downgraded Zentalis Pharma from Buy to Hold and set a new price target of $6.00 from $42.00 previously
Morgan Stanley downgraded Zentalis Pharma from Overweight to Equal-Weight and set a new price target of $8.00 from $38.00 previously
Wedbush downgraded Zentalis Pharma from Neutral to Underperform and set a new price target of $4.00 from $15.00 previously
Wells Fargo downgraded Zentalis Pharma from Overweight to Equal Weight
Wedbush downgraded Zentalis Pharma from Outperform to Neutral and set a new price target of $12.00 from $38.00 previously
Leerink Partners downgraded Zentalis Pharma from Outperform to Market Perform and set a new price target of $15.00
Cowen initiated coverage of Zentalis Pharma with a rating of Outperform
Wells Fargo initiated coverage of Zentalis Pharma with a rating of Overweight and set a new price target of $67.00
Julie Eastland appointed Chief Executive Officer, President and Director Ingmar Bruns, M.D., appointed Chief Medical Officer Scott Myers appointed to the Board of Directors as Chairperson SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced changes to its executive leadership team to support the Company as it plans and executes registrational studies for its lead product candidate, azenosertib. Julie Eastland has been appointed Chief Executive Officer, Pres
SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on November 1, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 79,500 shares of the Company's common stock and 21,000 restricted stock units to three newly hired employees. The stock options and restricted stock units were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022
SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on studies of azenosertib, the Company's novel, selective, and orally bioavailable inhibitor of WEE1. The FDA has cleared the Company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan. Zentalis will be working with clinical trial investigators to resume study a
SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the company will present preclinical data from its selective WEE1 inhibitor azenosertib at the European Society of Medical Oncology (ESMO) 2024 Congress, occurring September 13-17 in Barcelona, Spain. "The confluence of DNA damage induced by TOP1 inhibitors and cell cycle deregulation and genomic instability induced by azenosertib provides a mechanistic rationale for this combination, as well as mo
SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on September 3, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 16,000 shares of the Company's common stock to 2 newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individ
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ:ZNTL) into potential breaches of fiduciary duty by the Company's Board of Directors (the "Board"). Zentalis, headquartered in San Diego, CA, is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Newman Ferrara's investigation focuses on decisions made by the Board, without shareholder approval, the result of which significantly diminish shareholder value and do not benefit the Company. Considering the Co
$426.4M cash, cash equivalents and marketable securities as of June 30, 2024;Projected cash runway into mid-2026 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the quarter ended June 30, 2024, and highlighted recent corporate accomplishments. "While we faced challenges this quarter with regards to the ongoing partial clinical hold on azenosertib, we remain steadfast in our confidence in the program's t
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on August 1, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 282,500 shares of the Company's common stock to 11 newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individua
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on July 1, 2024, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 40,875 shares of the Company's common stock to five newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual
FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the
8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
10-Q - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
144 - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
10-Q - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
144 - Zentalis Pharmaceuticals, Inc. (0001725160) (Subject)
8-K - Zentalis Pharmaceuticals, Inc. (0001725160) (Filer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
$426.4M cash, cash equivalents and marketable securities as of June 30, 2024;Projected cash runway into mid-2026 SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the quarter ended June 30, 2024, and highlighted recent corporate accomplishments. "While we faced challenges this quarter with regards to the ongoing partial clinical hold on azenosertib, we remain steadfast in our confidence in the program's t
NEW YORK and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Luke Walker, M.D., to its Board of Directors. Dr. Walker is the Chief Medical Officer of Harpoon Therapeutics, a subsidiary of Merck & Co., Inc., Rahway, NJ, and brings nearly three decades of experience as a practicing oncologist and drug developer advancing new cancer therapies. "We are pleased to have Luke join our Board of Directors and contribute to the Company's pipeline
NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Kimberly Freeman as Chief Strategy Officer. In this role, she will support and implement Zentalis' long-term portfolio strategy. Ms. Freeman joins Zentalis with over 25 years of clinical development and strategic leadership experience, including deep expertise in oncology, particularly in gynecologic malignancies and the DNA damage response (DDR) pathway. "Kimberly brings an o
NEW YORK and SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Iris Roth, PhD, as Chief Operating Officer (COO). Dr. Roth joins Zentalis with over two decades of biopharmaceutical experience building and executing clinical and operational strategies, successfully advancing the development of multiple investigational therapies in oncology. "I am incredibly pleased to welcome Iris to Zentalis, rounding out our management team wit
NEW YORK and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Mark Lackner, PhD, as Chief Translational Officer, Head of Biomarker Strategy. Dr. Lackner, an esteemed cancer biologist, joins Zentalis with over two decades of oncology-focused drug development expertise, including significant experience in biomarker discovery and clinical biomarker strategies. "This year, we have prioritized strengthening our executive team and s
NEW YORK and SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Carrie Brownstein, MD, as Chief Medical Officer (CMO), effective October 3, 2022. Dr. Brownstein, a leading oncologist and hematologist by training, joins Zentalis with over two decades of medical and biopharmaceutical experience executing clinical program strategies across all phases of product development. "We are honored to welcome Carrie to our team as CMO, whe
NEW YORK and SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Zentalis™ Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Jan Skvarka, PhD, MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to Zentalis. "We are excited to welcome Jan, an experienced life sciences leader, to our Board of Directors," said Dr. Kimberly Blackwell, Chief Executive Officer of Zenta
NEW YORK and SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Andrea Paul, J.D., as General Counsel and Corporate Secretary, effective August 1, 2022. Ms. Paul brings several years of legal leadership experience in the healthcare industry to Zentalis. "I am delighted to welcome Andrea to our team. Her extensive expertise in managing complex legal and compliance matters will offer invaluable perspective as we drive forward our clinical plans. I am conf
Dave Johnson appointed as Chairman of the Board Anthony Sun, MD, former CEO of Zentalis, to remain CEO of joint venture, Zentera Therapeutics NEW YORK and SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that oncology clinical development veteran Kimberly Blackwell, MD, will succeed Anthony Sun, MD, as Chief Executive Officer (CEO). Dr. Blackwell is a current member of Zentalis' Board and previously served as Chief Medical Officer of Tempus Labs and held clin
NEW YORK & SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Enoch Kariuki, PharmD, to its Board of Directors. Dr. Kariuki is a highly accomplished finance executive, bringing over a decade of deep expertise in life sciences investment banking, strategic advising and business development to Zentalis. “We are pleased to welcome Enoch to our Board of Directors, and believe his experience as a financial leader in the healthcare sector will offer invaluable
Zentalis Pharma's (NYSE:ZNTL) short percent of float has fallen 5.5% since its last report. The company recently reported that it has 17.51 million shares sold short, which is 49.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 32.5 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short inter
UBS analyst Eliana Merle downgrades Zentalis Pharma (NASDAQ:ZNTL) from Buy to Neutral and lowers the price target from $28 to $5.
Gainers Molecular Partners (NASDAQ:MOLN) stock rose 39.1% to $11.07 during Thursday's regular session. The market value of their outstanding shares is at $367.3 million. Zentalis Pharma (NASDAQ:ZNTL) stock rose 36.83% to $5.67. The market value of their outstanding shares is at $402.2 million. Femasys (NASDAQ:FEMY) stock increased by 28.27% to $1.23. The market value of their outstanding shares is at $27.2 million. SeaStar Medical Holding (NASDAQ:ICU) shares rose 18.68% to $4.89. The market value of their outstanding shares is at $15.2 million. Nanoviricides (AMEX:NNVC) shares rose 17.68% to $1.93. The company's market cap stands at $22.8 million. CASI Pharmaceuticals (NASDAQ:CASI) sha
Gainers Geovax Labs (NASDAQ:GOVX) stock moved upwards by 72.1% to $1.91 during Wednesday's regular session. The company's market cap stands at $4.8 million. Nexalin Technology (NASDAQ:NXL) shares increased by 43.06% to $1.08. The market value of their outstanding shares is at $8.0 million. Vaxart (NASDAQ:VXRT) shares rose 33.45% to $0.7. The market value of their outstanding shares is at $123.8 million. Sunshine Biopharma (NASDAQ:SBFM) stock increased by 28.92% to $0.39. The market value of their outstanding shares is at $7.4 million. Portage Biotech (NASDAQ:PRTG) shares increased by 25.0% to $0.3. The company's market cap stands at $5.9 million. Silk Road Medical (NASDAQ:SILK) shares
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares rose 60.2% to $0.27 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.2 million. As per the press release, Q4 earnings came out 2 days ago. Mustang Bio (NASDAQ:MBIO) stock moved upwards by 31.21% to $0.98. The market value of their outstanding shares is at $27.7 million. Geovax Labs (NASDAQ:GOVX) shares increased by 24.32% to $1.38. The market value of their outstanding shares is at $3.4 million. Silk Road Medical (NASDAQ:SILK) stock increased by 23.67% to $26.8. The company's market cap stands at $1.0 billion. Onconetix (NASDAQ:ONCO) shares rose 18.91% to $0.19. The market value of their outs
Wells Fargo analyst Derek Archila downgrades Zentalis Pharma (NASDAQ:ZNTL) from Overweight to Equal-Weight and lowers the price target from $29 to $9.
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates. Quantum shares dipped 44.5% to $0.43 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Reliance Global Group, Inc. (NASDAQ:RELI) shares jumped 350% to $1.00 after the company issued an update on the pending acquisition of Spetner Associates. NLS Pharmaceutics AG (NASDAQ:NLSP) shares rose 166% to $0.3930 after jumping 30% on Monday. Actelis Networks, Inc. (NASDAQ:ASNS) climbed 80.9% to $2.08 after the company announced a partnership with Carahsoft Tech
Stifel analyst Bradley Canino maintains Zentalis Pharma (NASDAQ:ZNTL) with a Buy and lowers the price target from $32 to $10.
HC Wainwright & Co. analyst Andrew Fein maintains Zentalis Pharma (NASDAQ:ZNTL) with a Buy and lowers the price target from $40 to $20.